ArduiniRM, LiZ, RapozaA, et al.Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. Protein Expr Purif, 2004; 34(2):229–242; doi: 10.1016/j.pep.2003.11.004
2.
BakerDP, FetlerL, KeiserRT, et al.Weakening of the interface between adjacent catalytic chains promotes domain closure in Escherichia coli aspartate transcarbamoylase. Protein Sci, 1995; 4(2):258–267; doi: 10.1002/pro.5560040212
3.
BakerDP, KleanthousC, KeenJN, et al.Mechanistic and active-site studies on D(-)-mandelate dehydrogenase from Rhodotorula graminis. Biochem J, 1992; 281 (Pt 1)(Pt 1):211–218; doi: 10.1042/bj2810211
4.
BakerDP, LinEY, LinK, et al.N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem, 2006; 17(1):179–188; doi: 10.1021/bc050237q
5.
BakerDP, PepinskyRB, BrickelmaierM, et al.PEGylated interferon beta-1a: Meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J Interferon Cytokine Res, 2010; 30(10):777–785; doi: 10.1089/jir.2010.0092
6.
BakerDP, StebbinsJW, DeSenaE, et al.Glutamic acid 86 is important for positioning the 80's loop and arginine 54 at the active site of Escherichia coli aspartate transcarbamoylase and for the structural stabilization of the C1–C2 interface. J Biol Chem, 1994; 269(40):24608–24614.
7.
BasakAK, BakerDP, FewsonCA, et al.Preliminary crystallographic study of D(-)-mandelate dehydrogenase from Rhodotorula graminis. J Mol Biol, 1993; 233(4):781–783; doi: 10.1006/jmbi.1993.1552
8.
BocciaA, VirataC, LindnerD, et al.Peginterferon beta-1a shows antitumor activity as a single agent and enhances efficacy of standard of care cancer therapeutics in human melanoma, breast, renal, and colon xenograft models. J Interferon Cytokine Res, 2017; 37(1):20–31; doi: 10.1089/jir.2016.0027
9.
CalabresiPA, KieseierBC, ArnoldDL, et al.; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. Lancet Neurol, 2014; 13(7):657–665; doi: 10.1016/S1474-4422(14)70068-7
10.
HuX, MillerL, RichmanS, et al.A novel PEGylated interferon beta-1a for multiple sclerosis: Safety, pharmacology, and biology. J Clin Pharmacol, 2012; 52(6):798–808; doi: 10.1177/0091270011407068
11.
HuX, OlivierK, PolackE, et al.In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a. J Pharmacol Exp Ther, 2011; 338(3):984–996; doi: 10.1124/jpet.111.180661
12.
KieseierBC, ArnoldDL, BalcerLJ, et al.Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler, 2015; 21(8):1025–1035; doi: 10.1177/1352458514557986
13.
NguyenK, OlcerM, Howlett-PrietoQ, et al.Prolonged interferon stimulated gene and protein signatures in multiple sclerosis induced by PEGylated IFN-β-1a compared to non-PEGylated IFN-β-1a. J Interferon Cytokine Res, 2023; 43(3):108–120; doi: 10.1089/jir.2022.0238
14.
PepinskyRB, LePageDJ, GillA, et al.Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther, 2001; 297(3):1059–1066.
15.
PorriniAM, GambiD, RederAT. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol, 1995; 61(1):27–34; doi: 10.1016/0165-5728(95)00070-i
16.
RudickRA, RansohoffRM, PepplerR, et al.Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis. Ann Neurol, 1996; 40(4):618–627; doi: 10.1002/ana.410400412
17.
WangX, ChenM, WandingerKP, et al.IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: Relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol, 2000; 165(1):548–557; doi: 10.4049/jimmunol.165.1.548
